DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients
Table 1
Methylation levels of melanoma susceptibility genes in peripheral blood of melanoma patients and association with clinical characteristics.
Clinical characteristics of patients
BAP1
CDK4
CDKN2A
MC1R
MGMT
Promoter
Body
Promoter
Body
Promoter
Promoter
Promoter
Body
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
Melanomas number
1
18
0.04 ()
0.59 (0.01)
0.25 ()
0.32 (0.06)
(0.01)
0.36 (0.01)
0.45 ()
0.87 (0.02)
>1
21
0.03 ()
0.59 (0.01)
0.25 (8.)
0.33 (0.04)
(0.01)
0.36 (0.01)
0.45 ()
0.88 (0.02)
value
0.60
0.16
0.97
0.62
0.42
0.85
0.11
Breslow thickness*
<1
24
0.04 (9.5)
0.59 (0.02)
0.25 ()
0.33 (0.04)
0.08 (0.01)
0.36 (0.01)
0.45 ()
0.87 (0.02)
≥1
13
4.5 (6.7)
0.59 (0.01)
0.25 ()
0.33 (0.03)
0.07 (0.01)
0.36 (0.01)
0.45 ()
0.87 (0.01)
value
0.84
0.36
0.69
0.69
0.36
0.45
0.19
0.45
Clinical characteristics of patients
MITF (NM_000248 and NM_198158)
MITF (NM_006722)
MITF (NM_198159)
MITF (NM_198177)
Promoter
Body
Promoter
Body
Promoter
Body
Promoter
Body
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
Number of melanomas
1
18
0.93 (0.03)
0.94 (0.02)
0.78 (0.03)
0.87 (0.02)
0.08 (0.03)
0.73 (0.01)
0.79 (0.03)
0.91 (0.02)
>1
21
0.95 (0.02)
0.95 (0.02)
0.80 (0.03)
0.88 (0.01)
0.08 (0.03)
0.73 (0.01)
0.80 (0.02)
0.92 (0.01)
value
0.01
0.83
0.02
0.10
1.00
0.02
0.20
Breslow thickness*
<1
24
0.95 (0.03)
0.95 (0.02)
0.80 (0.03)
0.88 (0.02)
0.08 (0.02)
0.73 (0.01)
0.80 (0.03)
0.91 (0.02)
≥1
13
0.95 (0.02)
0.94 (0.02)
0.79 (0.03)
0.87 (0.01)
0.08 (0.03)
0.73 (0.01)
0.79 (0.02)
0.91 (0.01)
value
0.99
0.19
0.42
0.44
0.94
0.44
0.54
0.51
Clinical characteristics of patients
MITF (NM_198178)
PALB2
POT1 (NM_001042594)
POT1 (NM_015450)
Promoter
Body
Promoter
Body
Promoter
Body
Promoter
Body
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
Number of melanomas
1
18
0.94 (0.02)
0.92 (0.02)
0.24 ()
0.06 (0.01)
0.95 (0.01)
0.23 (0.01)
0.17 (0.01)
0.95 (0.02)
>1
21
0.93 (0.02)
0.93 (0.01)
0.23 ()
0.07 (0.01)
0.96 (0.02)
0.23 (0.01)
0.16 (0.01)
0.96 (0.01)
value
0.68
0.09
0.01
0.47
0.18
0.68
0.54
0.10
Breslow thickness*
<1
24
0.94 (0.02)
0.92 (0.02)
0.24 ()
0.07 (0.01)
0.95 (0.02)
0.23 (0.01)
0.16 (0.01)
0.96 (0.01)
≥1
13
0.92 (0.03)
0.92 (0.01)
0.23 ()
0.06 (0.01)
0.96 (0.01)
0.24 (0.01)
0.17 (0.01)
0.96 (0.01)
value
0.26
0.76
0.81
0.26
0.58
0.06
0.04
0.76
Clinical characteristics of patients
POT1 (NR_003102. NR_003103 and NR_003104)
TERT
TNFRSF10C
TNF
Promoter
Body
Promoter
Body
Promoter
Body
Promoter
Body
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
Melanomas number
1
18
0.17 (0.01)
0.50 (0.01)
0.58 (0.039)
0.86 (0.02)
0.38 (0.01)
0.12 (0.02)
0.21 (0.03)
0.67 (0.05)
>1
21
0.17 (0.01)
0.50 (0.02)
0.58 (0.043)
0.86 (0.01)
0.38 (0.01)
0.11 (0.02)
0.22 (0.03)
0.69 (0.07)
value
0.75
0.72
0.75
0.13
0.15
0.94
0.32
0.33
Breslow thickness*
<1
24
0.16 (0.01)
0.50 (0.02)
0.58 (0.046)
0.86 (0.02)
0.38 (0.01)
0.11 (0.02)
0.22 (0.03)
0.69 (0.07)
≥1
13
0.17 (0.01)
0.51 (0.01)
0.58 (0.028)
0.86 (0.01)
0.38 (0.01)
0.12 (0.02)
0.21 (0.03)
0.66 (0.05)
value
0.07
0.12
0.54
0.35
0.79
0.54
0.74
0.35
: number of samples; promoter: probes mapped at TSS1500, TSS200, 5′UTR, or 1st exon; mean of DNA methylation levels; SD: standard deviation; *Breslow thickness of high melanoma stage; values highlighted in bold are statistically significant ( < 0.05. Mann-Whitney test).
